Showing results (21-30 of 31) with videos related to

Sort By:
Pageof 4
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 18, 1999
Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndromeJ Rubin, J Ajani, W Schirmer, et al.
ESMO Open|July 5, 2022
Tislelizumab versus chemotherapy as second-line treatment of advanced or metastatic esophageal squamous cell carcinoma (RATIONALE 302): impact on health-related quality of lifeE Van Cutsem, K Kato, J Ajani, et al.
Bailliere'S Clinical Endocrinology and Metabolism|May 1, 1989
Gastrointestinal and pancreatic endocrine tumoursJ T Hall, S Wallace, C H Carrasco, et al.
Cancer|October 15, 1992
Phase II evaluation of fluorouracil and recombinant alpha-2a-interferon in previously untreated patients with pancreatic adenocarcinomaR Pazdur, J J Ajani, J L Abbruzzese, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 1998
Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagusD H Ilson, J Ajani, K Bhalla, et al.
British Journal of Cancer|August 2, 2006
Multicentre phase II pharmacokinetic and pharmacodynamic study of OSI-7904L in previously untreated patients with advanced gastric or gastroesophageal junction adenocarcinomaS Falk, A Anthoney, M Eatock, et al.
The New England Journal of Medicine|December 31, 1998
Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancerD P Kelsen, R Ginsberg, T F Pajak, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 6, 1999
Prognostic implications of response to preoperative infusional chemoradiation in locally advanced rectal cancerN A Janjan, J Abbruzzese, R Pazdur, et al.
European Journal of Cancer (Oxford, England : 1990)|February 5, 2020
Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 studyE Van Cutsem, K Muro, D Cunningham, et al.
ESMO Open|December 20, 2023
Tislelizumab versus chemotherapy as second-line treatment for European and North American patients with advanced or metastatic esophageal squamous cell carcinoma: a subgroup analysis of the randomized phase III RATIONALE-302 studyJ Ajani, F El Hajbi, D Cunningham, et al.
Pageof 4